INTRODUCTION: Phosphodiesterase-5a inhibition (PDE5i) leads to favorable changes in pulmonary hemodynamic and cardiac output (CO) in patients with advanced heart failure (HF) and reduced ejection fraction (HFrEF). The hemodynamic response to PDE5i could be heterogeneous and the clinical variables associated with these changes are scarcely investigated. MATERIALS AND METHODS: Of 260 patients with advanced HFrEF referred for advanced therapies [cardiac transplant/left ventricular assist device (LVAD)], 55 had pulmonary hypertension (PH) and fulfilled the criteria for the PDE5i vasoreactivity test. Right heart catheterization (RHC) was performed as a part of clinical evaluation before and after 20-mg intravenous sildenafil. Absolute and relative changes in pulmonary vascular resistance (PVR) were evaluated to assess hemodynamic response to PDE5i. Clinical, biochemical, and hemodynamic factors associated with PVR changes were identified. RESULTS: Sildenafil administration reduced PVR (- 45.3%) and transpulmonary gradient (TPG; - 34.8%) and increased CO (+ 13.6%). Relative change analysis showed a negative moderate association between baseline plasma potassium and changes in PVR (r = - 0.48; p = 0.001) and TPG (r = - 0.43; p = 0.005) after PDE5i. Aldosterone concentration shows a direct moderate association with PVR changes after PDE5i. A significant moderate association was also demonstrated between CO improvement and the severity of mitral (r = 0.42; p = 0.002) and tricuspid (r = 0.39; p = 0.004) regurgitation. CONCLUSION: We identified plasma potassium, plasma aldosterone level, and atrioventricular valve regurgitations as potential cofounders of hemodynamic response to acute administration of PDE5i. Whether modulation of potassium levels could enhance pulmonary vasoreactivity in advanced HFrEF deserves further research.

Department of Clinical Internal Anesthesiological and Cardiovascular Sciences Sapienza University Rome Italy

Institute for Clinical and Experimental Medicine Prague Czechia

See more in PubMed

Miller WL, Grill DE, Borlaug BA. Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure. JACC Heart Fail. (2013) 1:290–9. 10.1016/j.jchf.2013.05.001 PubMed DOI

Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol. (2001) 37:183–8. 10.1016/s0735-1097(00)01102-5 PubMed DOI

Lewis GD, Lachmann J, Camuso J, Lepore JJ, Shin J, Martinovic ME, et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation. (2007) 115:59–66. 10.1161/CIRCULATIONAHA.106.626226 PubMed DOI

Vachiery JL, Tedford RJ, Rosenkranz S, Palazzini M, Lang I, Guazzi M, et al. Pulmonary hypertension due to left heart disease. Eur Respir J. (2019) 53:1801897. PubMed PMC

Delgado JF, Gomez-Sanchez MA, Saenz de la Calzada C, Sanchez V, Escribano P, Hernandez-Afonso J, et al. Impact of mild pulmonary hypertension on mortality and pulmonary artery pressure profile after heart transplantation. J Heart Lung Transplant. (2001) 20:942–8. 10.1016/s1053-2498(01)00286-8 PubMed DOI

Zimpfer D, Fiane AE, Larbalestier R, Tsui S, Jansz P, Simon A, et al. Long-term survival of patients with advanced heart failure receiving an left ventricular assist device intended as a bridge to transplantation: the registry to evaluate the heartware left ventricular assist system. Circ Heart Fail. (2020) 13:e006252. 10.1161/CIRCHEARTFAILURE.119.006252 PubMed DOI

Argiriou M, Kolokotron SM, Sakellaridis T, Argiriou O, Charitos C, Zarogoulidis P, et al. Right heart failure post left ventricular assist device implantation. J Thorac Dis. (2014) 6:S52–9. PubMed PMC

Kormos RL, Teuteberg JJ, Pagani FD, Russell SD, John R, Miller LW, et al. Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. J Thorac Cardiovasc Surg. (2010) 139:1316–24. 10.1016/j.jtcvs.2009.11.020 PubMed DOI

Costard-Jackle A, Fowler MB. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol. (1992) 19:48–54. 10.1016/0735-1097(92)90050-w PubMed DOI

Drakos SG, Janicki L, Horne BD, Kfoury AG, Reid BB, Clayson S, et al. Risk factors predictive of right ventricular failure after left ventricular assist device implantation. Am J Cardiol. (2010) 105:1030–5. 10.1016/j.amjcard.2009.11.026 PubMed DOI

Melenovsky V, Al-Hiti H, Kazdova L, Jabor A, Syrovatka P, Malek I, et al. Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafil. J Am Coll Cardiol. (2009) 54:595–600. 10.1016/j.jacc.2009.05.021 PubMed DOI

Reichenbach A, Al-Hiti H, Malek I, Pirk J, Goncalvesova E, Kautzner J, et al. The effects of phosphodiesterase 5 inhibition on hemodynamics, functional status and survival in advanced heart failure and pulmonary hypertension: a case-control study. Int J Cardiol. (2013) 168:60–5. 10.1016/j.ijcard.2012.09.074 PubMed DOI

Tedford RJ, Hemnes AR, Russell SD, Wittstein IS, Mahmud M, Zaiman AL, et al. PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circ Heart Fail. (2008) 1:213–9. 10.1161/CIRCHEARTFAILURE.108.796789 PubMed DOI PMC

Ravichandran AK, LaRue SJ, Novak E, Joseph SA, Schilling JD. Sildenafil in left ventricular assist device is safe and well-tolerated. ASAIO J. (2018) 64:280–1. 10.1097/MAT.0000000000000626 PubMed DOI

Monzo L, Reichenbach A, Al-Hiti H, Borlaug BA, Havlenova T, Solar N, et al. Acute unloading effects of sildenafil enhance right ventricular-pulmonary artery coupling in heart failure. J Card Fail. (2021) 27:224–32. 10.1016/j.cardfail.2020.11.007 PubMed DOI

Sparrow CT, LaRue SJ, Schilling JD. Intersection of Pulmonary hypertension and right ventricular dysfunction in patients on left ventricular assist device support: is there a role for pulmonary vasodilators? Circ Heart Fail. (2018) 11:e004255. 10.1161/CIRCHEARTFAILURE.117.004255 PubMed DOI PMC

Kittipibul V, Blumer V, Angsubhakorn N, Hernandez GA, Chaparro S, Tedford RJ, et al. Phosphodiesterase-5 inhibitors and outcomes during left ventricular assist device support: a systematic review and meta-analysis. J Card Fail. (2021) 27:477–85. 10.1016/j.cardfail.2020.12.018 PubMed DOI

Al-Hiti H, Melenovsky V, Syrovatka P, Kettner J, Malek I, Kautzner J. Sildenafil is more selective pulmonary vasodilator than prostaglandin E1 in patients with pulmonary hypertension due to heart failure. Physiol Res. (2011) 60:303–8. 10.33549/physiolres.931951 PubMed DOI

Botha P, Parry G, Dark JH, Macgowan GA. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition. J Heart Lung Transplant. (2009) 28:676–82. 10.1016/j.healun.2009.04.013 PubMed DOI

Halliday SJ, Hemnes AR. Identifying “super responders” in pulmonary arterial hypertension. Pulm Circ. (2017) 7:300–11. 10.1177/2045893217697708 PubMed DOI PMC

Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. (2013) 309:1268–77. 10.1001/jama.2013.2024 PubMed DOI PMC

Gulati G, Grandin EW, Kennedy K, Cabezas F, DeNofrio DD, Kociol R, et al. Preimplant phosphodiesterase-5 inhibitor use is associated with higher rates of severe early right heart failure after left ventricular assist device implantation. Circ Heart Fail. (2019) 12:e005537. PubMed PMC

Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. (2015) 16:233–70. 10.1093/ehjci/jev014 PubMed DOI

Lancellotti P, Tribouilloy C, Hagendorff A, Popescu BA, Edvardsen T, Pierard LA, et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. (2013) 14:611–44. 10.1093/ehjci/jet105 PubMed DOI

Melenovsky V, Kotrc M, Borlaug BA, Marek T, Kovar J, Malek I, et al. Relationships between right ventricular function, body composition, and prognosis in advanced heart failure. J Am Coll Cardiol. (2013) 62:1660–70. 10.1016/j.jacc.2013.06.046 PubMed DOI

Kovacs G, Avian A, Pienn M, Naeije R, Olschewski H. Reading pulmonary vascular pressure tracings. How to handle the problems of zero leveling and respiratory swings. Am J Respir Crit Care Med. (2014) 190:252–7. 10.1164/rccm.201402-0269PP PubMed DOI

Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. (2019) 53:1801913. 10.1183/13993003.01913-2018 PubMed DOI PMC

Lewis GD, Semigran MJ. Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension. Curr Heart Fail Rep. (2004) 1:183–9. 10.1007/s11897-004-0007-6 PubMed DOI

Gettes LS. Electrolyte abnormalities underlying lethal and ventricular arrhythmias. Circulation. (1992) 85:I70–6. PubMed

Nunez J, Bayes-Genis A, Zannad F, Rossignol P, Nunez E, Bodi V, et al. Long-term potassium monitoring and dynamics in heart failure and risk of mortality. Circulation. (2018) 137:1320–30. 10.1161/circulationaha.117.030576 PubMed DOI

Boucherat O, Chabot S, Antigny F, Perros F, Provencher S, Bonnet S. Potassium channels in pulmonary arterial hypertension. Eur Respir J. (2015) 46:1167–77. 10.1183/13993003.00798-2015 PubMed DOI

McClenaghan C, Woo KV, Nichols CG. Pulmonary hypertension and ATP-sensitive potassium channels. Hypertension. (2019) 74:14–22. 10.1161/HYPERTENSIONAHA.119.12992 PubMed DOI PMC

Le Ribeuz H, Capuano V, Girerd B, Humbert M, Montani D, Antigny F. Implication of potassium channels in the pathophysiology of pulmonary arterial hypertension. Biomolecules. (2020) 10:1261. 10.3390/biom10091261 PubMed DOI PMC

Maron BA, Opotowsky AR, Landzberg MJ, Loscalzo J, Waxman AB, Leopold JA. Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study. Eur J Heart Fail. (2013) 15:277–83. 10.1093/eurjhf/hfs173 PubMed DOI PMC

Maron BA, Zhang YY, White K, Chan SY, Handy DE, Mahoney CE, et al. Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension. Circulation. (2012) 126:963–74. 10.1161/CIRCULATIONAHA.112.094722 PubMed DOI PMC

Huang W, Kingsbury MP, Turner MA, Donnelly JL, Flores NA, Sheridan DJ. Capillary filtration is reduced in lungs adapted to chronic heart failure: morphological and haemodynamic correlates. Cardiovasc Res. (2001) 49:207–17. 10.1016/s0008-6363(00)00223-6 PubMed DOI

Hoeper MM, Barbera JA, Channick RN, Hassoun PM, Lang IM, Manes A, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol. (2009) 54:S85–96. 10.1016/j.jacc.2009.04.008 PubMed DOI

Borlaug BA, Reddy YNV. The role of the pericardium in heart failure: implications for pathophysiology and treatment. JACC Heart Fail. (2019) 7:574–85. 10.1016/j.jchf.2019.03.021 PubMed DOI PMC

Ahmadi A, Spillner G, Johannesson T. Hemodynamic changes following experimental production and correction of acute mitral regurgitation with an adjustable ring prosthesis. Thorac Cardiovasc Surg. (1988) 36:313–9. 10.1055/s-2007-1022972 PubMed DOI

Yoran C, Yellin EL, Becker RM, Gabbay S, Frater RW, Sonnenblick EH. Mechanism of reduction of mitral regurgitation with vasodilator therapy. Am J Cardiol. (1979) 43:773–7. 10.1016/0002-9149(79)90077-8 PubMed DOI

Wharton J, Strange JW, Moller GM, Growcott EJ, Ren X, Franklyn AP, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med. (2005) 172:105–13. 10.1164/rccm.200411-1587OC PubMed DOI

Preston IR, Sagliani KD, Warburton RR, Hill NS, Fanburg BL, Jaffe IZ. Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. (2013) 304:L678–88. 10.1152/ajplung.00300.2012 PubMed DOI PMC

Boehm M, Arnold N, Braithwaite A, Pickworth J, Lu C, Novoyatleva T, et al. Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension. BMC Pulm Med. (2018) 18:41. 10.1186/s12890-018-0604-x PubMed DOI PMC

Pressure overload is associated with right ventricular dyssynchrony in heart failure with reduced ejection fraction